Forian Inc. announced that it has completed the combination of Helix Technologies, Inc. and Medical Outcomes Research Analytics, LLC. The combination empowers Forian to provide a unique suite of SaaS solutions, data management capabilities and proprietary data and analytics to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences, healthcare payor and provider segments as well as cannabis manufacturers, dispensaries, cultivators and regulators. Forian expects to begin trading on The Nasdaq Stock Market LLC under the symbol "FORA" on March 3, 2021. Shares of Helix will no longer trade on the OTCQB beginning on March 3, 2021 insofar as each share of Helix was exchanged for 0.05 shares of Forian common stock in the merger. There are approximately 32 million shares of Forian common stock outstanding on a fully diluted basis. Forian's proprietary data and integrated data management expertise, coupled with its team's deep background in SaaS-based platforms and commercial and clinical analytics, complement Helix's seed-to-sale compliance tracking and point of sale technologies for the quickly evolving and rapidly growing cannabis industry. The integration of Forian's data management platform and assets further differentiate Helix's BioTrack and Cannalytics solutions by infusing analytics into workflows to help customers make informed business decisions. Forian will improve current cannabis industry standards in data, analytics and reporting. Data from Helix's technology offerings will power new analytics for Forian healthcare clients interested in real world evidence pertaining to the safety, efficacy, quality and health outcomes associated with cannabinoid-based products.